Wednesday, July 26, 2023
MetaSight Diagnostics and Kahn-Sagol-Maccabi (KSM) collaborate on Multi-Omics Serum Screening Study.
The collaboration with KSM aims to apply multi-omics research to chronic and common conditions, with the goal of advancing early detection and monitoring of diseases like cancer, liver, cardiovascular, kidney, and neurological conditions.
The partnership's focus on creating a cost-effective multi-disease liquid biopsy suggests that they are exploring innovative ways to detect and diagnose multiple diseases from a single liquid sample, which could have significant implications for population health worldwide.
The collaboration between Maccabi and MetaSight supported by Thermo Scientific Vanquish liquid chromatography and Thermo Scientific Orbitrap mass spectrometry technology indicates that these scientific instruments play a role in enabling the research and analysis of the biological samples for the study.
Despite the significant progress made in liquid biopsies for detecting cancer, there still exists a critical gap in accurate, accessible, and affordable solutions for predicting and diagnosing other potentially life-threatening and debilitating conditions. This unique mass-spectrometry, multi-omics approach seems to be directed towards addressing the unmet need.
